3rd Quarter - Report

INOVIO PHARMACEUTICALS, INC. for INOVIO PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology and HPV cancers; Next Generation COVID-19 vaccines and boosters; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Continuing Resolution (CR), H.R. 6833, the Continuing Resolution and Ukraine Supplemental Appropriations Act; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Prevent Pandemic Act, S. 3799; DNA Medicines awareness.

LobbyistCovered position, as disclosed
COOKAB HASHEMI —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; White House Office

Bills named: H.R. 6833 (117th), H.R. 5585 (117th), S. 3799 (117th), H.R. 6963 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.